Campus Biotech Digital joins the EIT Deep Tech Talent Initiative to train the future biotech talents

> find out more

Paris, December 12, 2023 – Campus Biotech Digital, managed by a leading industrial consortium (bioMérieux, Sanofi, Servier), joins forces with the EIT Deep Tech Talent Initiative launched by the EIT (European Institute of Innovation and Technology), which aims to train one million people in Deep Tech between 2023 and 2025. The Campus will provide a set of 11 training courses dedicated to biomanufacturing, through its platform, to train future experts in the sector.

Meeting Europe’s new innovation agenda by training the talents of tomorrow

Launched in October 2022, the EIT Deep Tech Talent Initiative aims to bring together European Deep Tech players on a single platform to train one million talents between 2023 and 2025. This initiative is part of the New European Innovation Agenda and addresses the need for a skilled workforce, required to successfully exploit the new technologies driven by Deep Tech on a European scale, to make Europe a major player at the forefront of cutting-edge technological advances.

Through this collaboration, Campus Biotech Digital is committed to training biomanufacturing experts by offering a training program consisting of 11 courses to pass, covering the entire biomanufacturing value chain. Thanks to its platform and bilingual French/English courses, Campus Biotech Digital is committed to training 8,000 European talents by 2025. Interested candidates, whether students, employees, or jobseekers, can now apply for the courses on the EIT Deep Tech Talent Initiative website to deepen their knowledge of the sector and develop their careers.

This partnership with the EIT Community as part of their important Deep Tech Talent Initiative will enable Campus Biotech Digital to be a key player to address the talent shortage in the production of biomedicines. Our innovative and high-end curriculums will ensure the development of a workforce capable of meeting the evolving challenges of the complex value chain of the bio manufacturing and to answer to the strong needs from the manufacturers in a critical sector to the sovereignty of Europe” says Karim Vissandjee, General Manager of Campus Biotech Digital.

Promising sector for healthcare, biomanufacturing has been in constant evolution these past few years. Making biomedicines accessible to patients raises the challenges of industrialization and production on a local scale for all healthcare players. Many of them have joined our initiative and are committed to making Europe a major player of the Deep Tech industry through qualitative training. Today we have more than 100 organisations, including education providers, businesses and financial partners who joined the Pledge. We are delighted to welcome Campus Biotech Digital as a Pledger committed to making biomanufacturing more accessible and attractive to learners,” adds Paola Fantini, Education Director EIT Manufacturing.

Training courses combining technology, science, digital and data analysis for biomanufacturing

Campus Biotech Digital offers training courses covering the entire biomanufacturing value chain. Drawing on innovative, digital teaching solutions, the many courses promote an understanding of processes and the application of Good Manufacturing Practices (cGMPs).

The training courses, available on the platform, place the learner in a virtual environment simulating real-life conditions, enabling him or her to practice, to help anchor the memory and accelerate the assumption of a position.

Through this platform, the sector has set itself several objectives, including preparing its employees for the emergence of new technologies, making learning about bioproduction more effective with a “design thinking” approach, and leveraging digital training to facilitate initial and ongoing training for learners.

Press contact:
Laurine Vié – – 01 41 34 22 29


About bioMérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is a France based company. It is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – Code ISIN : FR0013280286
Reuters: BIOX.PA / Bloomberg : BIM.FP


About Novasep

Novasep provides cost-effective solutions for the sustainable production of molecules for the life sciences. Novasep offers a comprehensive range of services including process development, turnkey purification systems and contract manufacturing. We specialize in challenging active molecules for pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients, as well as fermentation and chemical commodities industries.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Stay informed

While waiting for registration to open, leave your details with us so we can send you our latest news.